JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

Days after JCR Pharmaceuticals signed a deal with AstraZeneca’s rare disease unit, the Japanese biopharma has secured a ...

JCR announced that it has entered into a license agreement with Alexion, for JCR’s new, proprietary JUST-AAV capsids to ...

The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR ...

Annexon offers speculative upside with Tanruprubart, targeting Guillain-Barré Syndrome's unmet needs. Click here to read my ...

Alexion Charitable Foundation announced it is giving the substantial grant to Roald Dahl's Marvellous Children's Charity.

JCR Pharma signs agreement with Alexion for proprietary JUST-AAV capsids to develop genomic medicines: Hyogo, Japan Thursday, July 10, 2025, 10:00 Hrs [IST] JCR Pharmaceuticals Co ...

The Paroxysmal Nocturnal Hemoglobinuria treatment market is experiencing significant expansion, driven by increasing disease awareness, rising preval ...

Alexion, AstraZeneca Rare Disease, will present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at the European Academy of Neurology (EAN) Annual Congress ...

How much longer will state leaders ignore Connecticut’s slow-moving exodus? That’s a question that will become increasingly pertinent as the state’s tax base continues to shrink. Businesses — and, ...

French biotech Inventiva has changed up its executive team as it continues to bet on experimental MASH therapy lanifibranor, ...